강예림, 고소희, & 이종혁. (2017). 우리나라의 건강보험 약가 사후관리제도 고찰 및 발전 방안. 약학회지, 61, 55-63.
권순만, 조윤민.(2015). 인구고령화와 건강보험. 시장과 정부 연구센터.
권혜영. (2012). 신약의 경쟁적 확산, 재정영향과 급여 및 가격결정 (박사학위논문, 서울대 학교 대학원).
김영숙, 김성옥(2009), 약품비 증가요인분석 및 관리방안. 국민건강보험공단.
김진수, 배성일, & 박일수. (2004). 건강보험급여비 동향 분석 모형 구축방안. 보건경제와 정책연구 (구 보건경제연구), 10(1), 113-134.
박실비아, 김대중, 박은자, 이슬기, 김소운. (2015). 약가 사후관리 제도 합리화 방안 연구.
보건사회연구원.
박은자. (2010). 노인의 만성질환치료제 비용부담. 보건복지포럼, 51-59.
변진옥, 김유리, 김주향. (2015). 인구기반 건강보험 약품비 지출양상 및 변동요인 분석. 건 강보험공단
배은영. (2007). 약제비 증가의 기여 요인과 영향 분석. 보건경제와 정책연구 (구 보건경제 연구), 13(2), 39-54.
원종욱, 성병찬, & 장인수. (2016). ARIMAX 모형을 적용한 건강보험지출 장기전망. 보건 경제와 정책연구 (구 보건경제연구), 22(2), 1-27.
장선미, 박찬미, 배그린, 이혜진, 김한상 (2010) 건강보험 약제비 변동요인 분석. 건강보험 심사평가원.
정현진, 문성웅, 서수라, 이정면. 주요국의 건강보장제도 현황과 개혁동향 : 제3권 대만.
2014, 국민건강보험공단, 건강보험정책연구원.
허순임, 정종찬, 이호용. (2006). 합리적 약제비 지출방안 연구. 국민건강보험공단.
참고문헌
Andre de Swaef, Toeriska Antonissen. Pharmaceutical Pricing and Reimbursement Information Belgium. OECD. 2007
Astolfi, R., L. Lorenzoni and J. Oderkirk (2012), “A Comparative Analysis of Health Forecasting Methods”, OECD Health Working Papers, No. 59, OECD Publishing, Paris.
http://dx.doi.org/10.1787/5k912j389bf0-en
Barnieh, L., Clement, F., Harris, A., Blom, M., Donaldson, C., Klarenbach, S., Manns, B.
(2014). A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development. PloS one, 9(3), e90434.
CEPS(French Healthcare Products Pricing Committee). 2014/2015 Annual Report.
Chernew, M. E., Smith, D. G., Kirking, D. M., & Fendrick, A. M. (2001). Decomposing pharmaceutical cost growth in different types of health plans. The American journal of managed care, 7(7), 667.
Cristel Zuidberg. The pharmaceutical system of the netherlands. 2010. Veienna
Dylst, P., Vulto, A. G., & Simoens, S. (2014). Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability. Expert review of pharmacoeconomics & outcomes research, 14(3), 345-353.
Emil Aho, Pontus Johansson, Gunilla Rönnholm. International price comparison of pharmaceuticals TLV. 2016
Fan, J. X., Sharpe, D. L., & Hong, G. S. (2003). Health care and prescription drug spending by seniors. Monthly Lab. Rev., 126, 16.
Fraeyman, J. (2014). The role of different actors in optimising pharmaceutical expenditures in Belgium (Doctoral dissertation, University of Antwerp).
Fogel, R. W. (2009). Forecasting the cost of US health care in 2040. Journal of Policy Modeling, 31(4), 482-488.
Gerdtham, U. G., & Lundin, D. (2004). Why did drug spending increase during the 1990s?. Pharmacoeconomics, 22(1), 29-42.
Gerdtham, UG., Johannesson, M., Gunnarsson, B. et al. Pharmacoeconomics (1998) 13:
127. https://doi.org/10.2165/00019053-199813010-00012
Gerdtham, U. G., Johannesson, M., Gunnarsson, B., Marcusson, M., & Henriksson, F.
(1998). The effect of changes in treatment patterns on drug expenditure.
Pharmacoeconomics, 13(1), 127-134.
Gruenberg, E. M. (1977). The failures of success. The Milbank Memorial Fund Quarterly.
Health and Society, 3-24.
Helga Festøy, Anne Helen Ognøy. PPRI Pharma Profile Norway 2015.
Kanavos, P., Seeley, E., & Vandoros, S. (2010). Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium. Enterprise and Industry, European Commission.
Lorenzoni, L., Morgan, D., Murakami, Y., & James, C. (2015). Public expenditure projections for health and long-term care for China until 2030.
Manton, K. G. (1982). Changing concepts of morbidity and mortality in the elderly population. The Milbank Memorial Fund Quarterly. Health and Society, 183-244.
Morgan, S. G. (2002). Quantifying components of drug expenditure inflation: the British Columbia seniors' drug benefit plan. Health services research, 37(5), 1243-1266.
Morgan, S. G., Agnew, J. D., & Barer, M. L. (2004). Seniors’ prescription drug cost inflation and cost containment: evidence from British Columbia. Health Policy, 68(3), 299-307.
참고문헌
Morgan, S. (2005). Drug expenditure trends in the Canadian provinces: magnitude and causes from 1998 to 2004. Healthcare policy, 1(1), 85.
Morgan, S., & Cunningham, C. (2011). Population aging and the determinants of healthcare expenditures: the case of hospital, medical and pharmaceutical care in british columbia, 1996 to 2006. Healthcare Policy, 7(1), 68.
Mueller, C., Schur, C., & O'connell, J. (1997). Prescription drug spending: the impact of age and chronic disease status. American Journal of Public Health, 87(10), 1626-1629.
Murthy, V. N., & Okunade, A. A. (2016). Determinants of US health expenditure:
Evidence from autoregressive distributed lag (ARDL) approach to cointegration. Economic Modelling, 59, 67-73.
Newhouse, J. P. (1992). Medical care costs: how much welfare loss?. The Journal of Economic Perspectives, 6(3), 3-21.
Paris, V., Docteur, E. Pharmaceutical Pricing and Reimbursement Policies in Germany.
OECD. 2008
PMPRB. 2006. Pharmaceutical Trends Overview Report: Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, and First Nations and Inuit Health Branch of Health Canada 1997–.1998
to 2003–.2004. Ottawa: Patented Medicine Prices Review Board.
PMPRB. 2013.The Drivers of Prescription Drug Expenditures –.A Methodological Report Ottawa: Patented Medicine Prices Review Board.
Reinhard Busse, Miriam Blümel. Germany health system review. Health Systems in Transition. Vol.16 No.2 2014
Steinberg, E. P., Gutierrez, B., Momani, A., Boscarino, J. A., Neuman, P., & Deverka, P.
Sambamoorthi, U., D. Shea, S. Crystal (2003). Total and Out-of-Pocket Expenditures for Prescription Drugs Among Older Persons. The Gerontologist. 43(3): 345-359.
Sophie Delcroix Lopes, Christian Marty, Driss Berdai. PHIS Pharma Profile France 2011, Sohpie Gerkens, Sherry Merkur. Belgium Health System review. Health systems in transition. Vol.12 No.5. 2010
The Federal Joint committee Decisions on Health Benefits. G-BA(Gemeinsamer Bundesausschuss). 2017
Neuman T., Cubanski, J., Huang, T., Damico, A.(2015). The rising cost of living longer: Analysis of Medicare Spending by Age for Beneficiaries in Traditional Medicare. Kizer foundation
http://www.kff.org/medicare/report/the-rising-cost-of-living-longer-analysis-of-medicare-spen ding-by-age-for-beneficiaries-in-traditional-medicare/view/footnotes/
Vogler, S., Gombocz, M., & Zimmermann, N. (2017). Tendering for off‐patent outpatient medicines: lessons learned from experiences in Belgium, Denmark and the Netherlands.
Journal of Pharmaceutical Health Services Research.
Wolff, J. L., Starfield, B., & Anderson, G. (2002). Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Archives of internal medicine, 162(20), 2269-2276.
https://assurance-maladie-astuces.com/tarif-forfaitaire-de-responsabilite-tfr/
https://www.tlv.se/In-English/pharmacy-new/substituting-medicines-at-the-pharmacy/Product -of-the-month/
BGMA(British generic manufacturers association)
http://www.britishgenerics.co.uk/about-generics/industry-overview BGMA(British generic manufacturers association)
참고문헌
http://www.britishgenerics.co.uk/about-generics/the-generics-industry
Online HiT for Belgium, Financing of public pharmaceutical expenditure by pharmaceutical companies.
http://www.hspm.org/countries/belgium25062012/livinghit.aspx?Section=5.6%20Pharmaceuti cal%20care&Type=Section#13Financingofpublicpharmaceuticalexpenditurebypharmaceutical companies
Online HIT for Belgium - HSPM. Dispensing of the drug amongst the cheapest for prescriptions under the International Nonproprietary Name(INN)(April 1, 2012)
http://www.hspm.org/countries/belgium25062012/livinghit.aspx?Section=5.6%20Pharmaceuti cal%20care&Type=Section#53Newmodalitiesonthepaymentofcontributionsontheturnoverofph armaceuticals
Online HIT for Spain. HSPM
http://www.hspm.org/countries/spain25062012/livinghit.aspx?Section=6.6%20Pharmaceutical
%20care&Type=Section#19Changesinreferencepricingsystem The Danish medicines agency
https://laegemiddelstyrelsen.dk/en/reimbursement/prices/